Brief Description
Resvita Biosciences seeks to restore and maintain the vitality of the skin by properly considering the skin microbiome as part of the human body. A harmless skin probiotic will continuously deliver the therapy that a body would to maintain skin health.
Through synthetic biology and metabolic engineering, the company's goal is to develop a safe and versatile skin microbial platform that can address the causes of skin aging and disease. Resvita Biosciences has a unique patented approach, a rich product pipeline, clear regulatory advantages, and an experienced scientific management team.
The company is developing multiple anti-aging products, an investigational drug to treat an orphan skin disease, and treatments for inflammatory skin diseases like eczema and psoriasis.
Amin Zargar and Jay Keasling co-founded ResVita Bio to commercialize discoveries made while Zargar was a postdoc in Keasling's lab at UC Berkeley.
Timeline
- 2021. Company founded
Inventors
Jay Keasling, Amin Zargar